P-287 Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions

CRC is the second most commonly diagnosed cancer and a leading cause of death in Europe. Today, median overall survival for patients (pts) with mCRC ∼30 months. The treatment strategy normally includes combination chemotherapy or without biological treatment. primary endpoint our study was to describe retrospectively disease’s clinical pattern sequence pathway who had received three lines real-life by using natural language processing (NLP). We explored how NLP can extract interpret information from patients' electronic health records (EHRs). This multicentre, observational retrospective based on secondary use 27,840,957 real-world data captured EHRs, which, 1,521,128 were obtained 1,608pts started 1st-line Artificial Intelligence techniques developed Medsavana. 217 pts 1st line reached 3rd during period (PAS population). A cross-sectional analysis performed over attended any 5 participating hospitals 2013 2017. In PAS population, 135pts male (62.2%) mean age 63.7 years. By time started, 31pts (14.3%) ECOG reported, 29pts (96.3%) 0-1 69pts (31.8%) showed tumour location at left colon. 143pts (65,9%) available eHCR their KRAS mutational profile, 110pts (50.7%) NRAS status reported Microsatellite Instability BRAF detected directly free text 25pts (11,5%) 13pts (6%) respectively. Complete sequencing across described 217pts. 95 (43.8%) Chemo+AntiVEGF, 99pts (45.6%) Chemo+AntiVEGF 2nd 61pts (28.1%) chemo+AntiVEFG. For Chemo+antiEGFR, 50 (23%) line, 32pts (14.7%) 42pts (19.4%) line. Finally, there 70pts (32%) Chemo alone, 78pts (35.9%) 84pts (38.7%) alone. Through this approach, characteristics patterns real world settings are consistent previous published mCRC. To minimise limitations caused heterogeneity, higher levels standardisation recording should be achieved. represents new exploratory approach evidence studies. These Data represent potential opportunity explore improvement management these patients.